Novo’s oral semaglutide hits targets in diabetics with renal impairment
Novo Nordisk says trial data show an oral formulation of its GLP-1 analogue semaglutide provided superior HbA1c and weight reductions versus placebo in people with type II diabetes and renal impairment.
Read More
